Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
E Gabriela Chiorean, Daniel Von Hoff, Yin Wan, Sandra Margunato-Debay, Marc Botteman & David Goldstein. (2018) Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer. Cancer Management and Research 10, pages 1389-1396.
Read now
Read now
Caitlyn T. Solem, Youngmin Kwon, Ruchit M. Shah, Abdalla Aly & Marc F. Botteman. (2018) Systematic review and benchmarking of Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) in oncology. Expert Review of Pharmacoeconomics & Outcomes Research 18:3, pages 245-253.
Read now
Read now
Bengt Glimelius. (2016) Any progress in pancreatic cancer?. Acta Oncologica 55:3, pages 255-258.
Read now
Read now
Articles from other publishers (17)
Louise Skau Rasmussen, Stine B. Winther, Inna M. Chen, Britta Weber, Lise Ventzel, Gabor Liposits, Julia Sidenius Johansen, Sönke Detlefsen, Ida Egendal, Susy Shim, Signe Christensen, Per Pfeiffer & Morten Ladekarl. (2023) A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01). BMC Cancer 23:1.
Crossref
Crossref
Hedy L. Kindler, Hyun Kyoo Yoo, Robert Hettle, Karen Y. Cui, Seongjung Joo, Gershon Y. Locker & Talia Golan. (2023) Patient‐centered outcomes in the POLO study of active maintenance olaparib for germline BRCA‐mutated metastatic pancreatic cancer. Cancer 129:9, pages 1411-1418.
Crossref
Crossref
C. H. Lee, Y. WanA. SmithR. XieR. J. Motzer. (2022) Quality-adjusted time without symptoms or toxicity (Q-TWiST) for lenvatinib plus everolimus versus everolimus monotherapy in patients with advanced renal cell carcinoma. Cancer Urology 17:4, pages 54-64.
Crossref
Crossref
Chung-Han Lee, Yin Wan, Alan Smith, Ran Xie & Robert J. Motzer. (2021) Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma. European Urology Open Science 31, pages 1-9.
Crossref
Crossref
P. G. Corrie, W. Qian, B. Basu, J. W. Valle, S. Falk, C. lwuji, H. Wasan, D. Palmer, M. Scott-Brown, J. Wadsley, S. Arif, J. Bridgewater, D. Propper, R. Gillmore, A. Gopinathan, R. Skells, P. Bundi, R. Brais, K. Dalchau, L. Bax, A. Chhabra, A. Machin, A. Dayim, K. McAdam, S. Cummins, L. Wall, R. Ellis, A. Anthoney, J. Evans, Y. T. Ma, C. Isherwood, A. Neesse, D. Tuveson & D. I. Jodrell. (2020) Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. British Journal of Cancer 122:12, pages 1760-1768.
Crossref
Crossref
Alexandra R. Lewis, Rille Pihlak & Mairéad G. McNamara. (2018) The importance of quality-of-life management in patients with advanced pancreatic ductal adenocarcinoma. Current Problems in Cancer 42:1, pages 26-39.
Crossref
Crossref
Markus Kieler, Matthias Unseld, Daniela Bianconi & Gerald W. Prager. (2017) Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer. memo - Magazine of European Medical Oncology 10:3, pages 136-140.
Crossref
Crossref
Uwe Pelzer, Jean-Frédéric Blanc, Davide Melisi, Antonio Cubillo, Daniel D Von Hoff, Andrea Wang-Gillam, Li-Tzong Chen, Jens T Siveke, Yin Wan, Caitlyn T Solem, Marc F Botteman, Yoojung Yang, Floris A de Jong & Richard A Hubner. (2017) Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. British Journal of Cancer 116:10, pages 1247-1253.
Crossref
Crossref
Vincent Picozzi, Siva Narayanan, X. Henry Hu & Jeffrey Vacirca. (2016) Health-Related Quality of Life in Patients with Metastatic Pancreatic Cancer. Journal of Gastrointestinal Cancer 48:1, pages 103-109.
Crossref
Crossref
Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato & Masao Tanaka. (2017) Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study. ESMO Open 2:1, pages e000151.
Crossref
Crossref
Marwan Ghosn, Tony Ibrahim, Tarek Assi, Elie El Rassy, Hampig Raphael Kourie & Joseph Kattan. (2016) Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. World Journal of Gastroenterology 22:46, pages 10124.
Crossref
Crossref
C J Langer, V Hirsh, I Okamoto, F-J Lin, Y Wan, S Whiting, T J Ong, M F Renschler & M F Botteman. (2015) Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel. British Journal of Cancer 113:1, pages 20-29.
Crossref
Crossref
Giovanni Lo Re, Davide A. Santeufemia, Luisa Foltran, Ettore Bidoli, Stefano M.M. Basso & Franco Lumachi. (2015) Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: A single institutional experience. Oncotarget 6:10, pages 8255-8260.
Crossref
Crossref
Giuseppe Aprile. (2015) Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update. World Journal of Gastroenterology 21:41, pages 11793.
Crossref
Crossref
Deepak Chitkara, Anupama Mittal & Ram I. Mahato. (2015) miRNAs in pancreatic cancer: Therapeutic potential, delivery challenges and strategies. Advanced Drug Delivery Reviews 81, pages 34-52.
Crossref
Crossref
Abdur R. Shakir. (2014) A Near-Complete Response to Treatment with Gemcitabine plus nab®-Paclitaxel in a Patient with Metastatic Pancreatic Cancer and Poor Performance Status: A Case Report. Case Reports in Oncology 7:3, pages 711-717.
Crossref
Crossref
Sheridan M. Hoy. (2014) Albumin-Bound Paclitaxel: A Review of Its Use for the First-Line Combination Treatment of Metastatic Pancreatic Cancer. Drugs 74:15, pages 1757-1768.
Crossref
Crossref